TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02266134

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Implementation of Measurement Based Care
Description: Measurement-based care in this study is the practice of basing psychotherapeutic services on the results of the Patient Health Questionnaire (PHQ-9); the implementation of measurement-based care will be standardized such that clinicians will be encouraged to administer the PHQ-9 to depressed clients before each session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Implementation of Measurement Based Care
Description: Measurement-based care in this study is the practice of basing psychotherapeutic services on the results of the Patient Health Questionnaire (PHQ-9); the implementation of measurement-based care will be standardized such that clinicians will be encouraged to administer the PHQ-9 to depressed clients before each session.
Study: NCT03621501

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: At the index procedure, the culprit lesion (cause of complaints/acute coronary syndrome) will be treated according to standard of care with a Biotronik Orsiro DES (Sirolimus-Eluting stent). If there are additional significant lesions besides the culprit lesion, patients will be randomized to direct complete revascularization or staged complete revascularization. In the direct complete revascularization group all lesions will be treated during the index procedure. In the staged complete revascularization group, only the culprit lesion will be treated during the index procedure. The remaining significant lesions will be treated later but within six weeks after the index procedure. In both arms the additional lesions will also be treated with Biotronik Orsiro DES (Sirolimus-Eluting stent).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: At the index procedure, the culprit lesion (cause of complaints/acute coronary syndrome) will be treated according to standard of care with a Biotronik Orsiro DES (Sirolimus-Eluting stent). If there are additional significant lesions besides the culprit lesion, patients will be randomized to direct complete revascularization or staged complete revascularization. In the direct complete revascularization group all lesions will be treated during the index procedure. In the staged complete revascularization group, only the culprit lesion will be treated during the index procedure. The remaining significant lesions will be treated later but within six weeks after the index procedure. In both arms the additional lesions will also be treated with Biotronik Orsiro DES (Sirolimus-Eluting stent).
Study: NCT00182468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening for intimate partner violence
Description: Women are screened for intimate partner violence prior to seeing a health care provider.
Study: NCT00802880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Study: NCT00823186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phyxol(Paclitaxel)
Description: Paclitaxel is 5ß,20-Epoxyl-1,2α,4,7,β 10 β,13 α-hexahydroxytax-11-en-9-one 4,10~-diacetae 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisocerine
Study: NCT00983242

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: A single dose of 0.6 mg colchicine administered alone at 8am on Day 1 after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil HCl ER
Description: One 240 mg verapamil HCl ER tablet taken at 8am on Days 15-18 without regard to meals and along with colchicine at 8am on Day 19 after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: A single dose of 0.6 mg colchicine administered along with verapamil HCL ER at 8 am on Day 19 after an overnight fast of at least 10 hours.
Study: NCT04374149

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Plasma Exchange
Description: TPE, five single plasma volume exchanges over 7 days (every day x 2 then every other day x 3) with albumin or FFP replacement if underlying coagulopathy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Plasma Exchange
Description: TPE, five single plasma volume exchanges over 7 days (every day x 2 then every other day x 3) with albumin or FFP replacement if underlying coagulopathy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: TPE, five single plasma volume exchanges over 7 days (every day x 2 then every other day x 3) with albumin or FFP replacement if underlying coagulopathy combined with ruxolitinib 5mg po BID beginning day prior to first TPE and continuing BID for total of 14 days.
Study: NCT02014545

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucanthone
Description: The dose of lucanthone to be administered will be calculated based on the patient's body weight. The dose to be given will be 250 bid, 250 tid or 375 tid dependent upon study progression.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Only standard treatment of whole brain radiation therapy is done.
Study: NCT02204111

Intervention type: OTHER
Intervention: Intervention
Description: Individualized treatment proposals (e.g. pain therapy, physiotherapy, psychological contact) from expert consensus, based on Patient Reported Outcomes
Study: NCT04008667

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupoint application
Description: Acupoint application: The patients start using the acupoint application on the umbilical Shenque point in 2 hours after surgery, 1 or 2 times a day, lasting 5 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fake acupoint application
Description: Fake acupoint application: The patients start using the fake acupoint application on the umbilical Shenque point in 2 hours after surgery, 1 or 2 times a day, lasting 5 days.
Study: NCT03518463

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced recovery after surgery (ERAS)
Description: The ERAS arm was exposed to standard preoperative, intraoperative and postoperative ERAS protocols of care. However, some were modified to our local resources and requirements as well as to the emergency nature of the surgeries.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Enhanced recovery after surgery (ERAS)
Description: The ERAS arm was exposed to standard preoperative, intraoperative and postoperative ERAS protocols of care. However, some were modified to our local resources and requirements as well as to the emergency nature of the surgeries.
Study: NCT03194204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline Tablets
Description: MMP-3 and MMP-9 will be done with blood samples using ELISA technique CIMT will be done using colored doppler ultrasound

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline Tablets
Description: MMP-3 and MMP-9 will be done with blood samples using ELISA technique CIMT will be done using colored doppler ultrasound
Study: NCT04120350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: In phase 1b study, a 3+3 design dose- escalation will be taken. 3 levels should be tested, 15/20/25mg orally d1-14, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol.~\[update 02-Jun-2020: the phase Ib trial has finished,and no MDT was obsevered in 25mg group. So the recommanded phase II dose was 25mg.\] In phase II study, 25mg daily is considered as an experiment dose for the induction cycles.~In both phase Ib and II study, the does of lenalidomide maintenance is fixed to 25mg orally d1-21 every 28 days for 1 cycle. The duration of maintenance is 2 years.
Study: NCT02736474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: 3 tablets（15mg） once per day in the first two weeks，then Naltrexone 5 tablets（25mg） once per day during the rest of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Naltrexone
Description: Placebo Naltrexone created and masked by the pharmacy to be used as a control.
Study: NCT04259437

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Protein, Energy Dense Nutritional Supplement
Description: Ready to drink oral supplement
Study: NCT02736474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: 1 capsule（150mg） once per day in the first two weeks，then 2 capsules（300mg） once per day during the rest of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Bupropion
Description: Placebo Bupropion created and masked by the pharmacy to be used as a control.
Study: NCT01369069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV insulin to maintain target glucose concentration of 80-130 mg/dL
Description: Intervention is to keep glucose concentration 80-130 mg/dL for up to 72 hours after randomization. IV insulin drip will be used to maintain glucose target.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL
Description: Sliding scale sub q insulin given will be given up to 4 times per day based on glucose concentration. It will be given only if glucose concentration greater than or equal to 180 mg/dL.
Study: NCT04280081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally
Study: NCT00821756

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OPAC (Outreach, Problem solving, Adherence, Continuity)
Description: Assertive outreach immediately after the suicide attempt with about 8 home visits plus contact by telephone, phone messages, e-mails. Duration of intervention 6 months.
Study: NCT02483351

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liberal Red Blood Cell Transfusion Strategy
Description: RBC Transfusion strategy with hemoglobin trigger of 100g/L
Study: NCT03941964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax tablets were to be taken orally once daily with a meal and water in the morning at approximately the same time each day. Tablets were to be swallowed whole and not chewed, crushed, or broken prior to swallowing. On the days that the participant received either azacitidine or decitabine, venetoclax was dosed in clinic and administered prior to these agents.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax tablets were to be taken orally once daily with a meal and water in the morning at approximately the same time each day. Tablets were to be swallowed whole and not chewed, crushed, or broken prior to swallowing. On the days that the participant received either azacitidine or decitabine, venetoclax was dosed in clinic and administered prior to these agents.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: The azacitidine infusion was prepared and administered per the package insert and given either subcutaneously or intravenously, per institutional practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: The decitabine infusion was prepared and administered per the package insert and given intravenously, per institutional practice.
Study: NCT00604318

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rhTSH
Description: The patients will be randomised to either T3 (Liothyronine) pause related to the first radioiodine treatment and Thyrogen injection with continuing Liothyronine treatment related to the second treatment/uptake - or Thyrogen related to the first treatment and T3 pause related to the second treatment /uptake.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhTSH
Description: The patients will be randomised to either T3 (Liothyronine) pause related to the first radioiodine treatment and Thyrogen injection with continuing Liothyronine treatment related to the second treatment/uptake - or Thyrogen related to the first treatment and T3 pause related to the second treatment /uptake.
Study: NCT04469387

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limited decompressions at adjacent segment with asymptomatic pre-existing spinal canal stenosis
Description: In terms of limited decompression at the adjacent segment, partial laminotomy, flavectomy, and bilateral medial facetectomies up to the pedicle will be performed. Complete laminectomy and destroy of posterior ligament complex will be avoided.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Responsible segments fused
Description: In terms of responsible segments fused, L4-5 and L5-S1 were fused using posterior lumbar interbody fusion (PLIF).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Responsible segments fused
Description: In terms of responsible segments fused, L4-5 and L5-S1 were fused using posterior lumbar interbody fusion (PLIF).
Study: NCT03958864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: CC-90001
Study: NCT01555034

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: movement therapy
Description: exercise, nutrition, movement therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise plus nutrition
Description: exercise, nutrition
Study: NCT02483351

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive Red Blood Cell Transfusion Strategy
Description: Optional RBC Transfusion with hemoglobin trigger of \<=80g/L
Study: NCT04602299

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Set the minimum time of gastroscopy
Description: This study contains 2 stages. At the first stage, no interventions are implemented. The researchers just observe the actual procedure time of gastroscopy. At the second stage, a minimal procedure time is set based on the observational results of the first stage.
Study: NCT04584645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted digital intervention
Description: Messages that provide informational content on the influenza vaccine (sourced from the Centers for Disease Control and Prevention and the American Heart Association), specific information about influenza and cardiovascular disorders, and behavioral prompts (e.g., reminders) surrounding influenza vaccination behaviors.
Study: NCT01654536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciclesonide nasal aerosol
Description: ciclesonide nasal aerosol 74 mcg (given as 1 actuation per nostril of 37 mcg ciclesonide nasal aerosol)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ciclesonide nasal spray
Description: ciclesonide nasal spray 200 mcg (given as 2 actuations per nostril of 50 mcg ciclesonide nasal spray)
Study: NCT02554448

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ISET system
Description: Use ISET system to test the number of CTCs from patients before and during treatment.
Study: NCT00276744

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
Study: NCT04239066

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tourniquet
Description: tubularized incided plate (TIP) urethroplasty plus tourniquet

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-tourniquet
Description: tubularized incided plate (TIP) urethroplasty plus non-tourniquet
Study: NCT00276744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitomycin C
Description: Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rapamycin
Description: Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
Study: NCT02171520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate generation I

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran etexilate generation II
Study: NCT02771912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol and excipients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Qualitative composition of Propofol lipuro 2% excipients
Study: NCT01462097

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: 12 months of aerobic exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: 12 months of health education sessions
Study: NCT02364752

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Draw

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Draw

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Draw

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Loop Diuretic Withdrawal/Salt Load
Study: NCT03260673

Intervention type: OTHER
Intervention: specular microscope
Description: The corneal endothelial cell density, variation in endothelial cell size (CV), percentage of hexagonal cells, and central corneal thickness(CCT) were recorded at baseline and at 3 months postoperatively.

Intervention type: OTHER
Intervention: specular microscope
Description: The corneal endothelial cell density, variation in endothelial cell size (CV), percentage of hexagonal cells, and central corneal thickness(CCT) were recorded at baseline and at 3 months postoperatively.
Study: NCT02364752

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Loop Diuretic Withdrawal/Salt Load
Study: NCT03371303

Intervention type: OTHER
Intervention: collection of prescription data
Description: collection of prescription data before and after a hospitalization

Intervention type: OTHER
Intervention: collection of prescription data
Description: collection of prescription data before and after a hospitalization

Intervention type: OTHER
Intervention: collection of prescription data
Description: collection of prescription data before and after a hospitalization

Intervention type: OTHER
Intervention: collection of prescription data
Description: collection of prescription data before and after a hospitalization
Study: NCT00906828

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levodopa/carbidopa
Description: intestinal gel, continuous infusion (daytime or 24-hour)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entacapone
Description: Tablet, 200 mg, given twice during the study at t=0h and t=5hrs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolcapone
Description: Tablet, 100 mg, given twice during study, at t=0h and t=5hrs.
Study: NCT03061227

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous glucagon
Description: Randomized application of glucagon or saline during oral glucose tolerance test

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous saline
Description: Randomized application of glucagon or saline during oral glucose tolerance test
Study: NCT03099512

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SFE
Description: The 'short foot exercise' has been described as a means to isolate contraction of the plantar intrinsic muscles.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercises which improves muscle strength, ROM...

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercises which improves muscle strength, ROM...
Study: NCT01564485

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac CT
Description: A cardiac CT involves a non-invasive test of the coronary arteries.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual medical care
Description: Patients would be treated by their primary care physicians with usual medical care with drugs such as lipid lowering medication, blood pressure lowering medications, and blood glucose lowering medications. The study will not specify which drugs to use and will it up to the individual physician's discretion.